This article is more than 5 years old. Information may no longer be current.

LADARVision receives approval for customized surgery

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ORLANDO, Fla. — Alcon’s excimer laser system for wavefront-guided customized refractive surgery received marketing approval from U.S. regulators, the company announced.

According to a news release issued during the American Academy of Ophthalmology meeting here, the LADARVision 4000 excimer laser and the LADARWave wavefront measuring device make up the first system to receive Food and Drug Administration approval for wavefront-guided customized LASIK surgery.

The FDA approved the system for the correction of myopia between the ranges of 0 D to -7 D with up to 0.5 D of cylinder, according to a company representative.

“Wavefront-guided customized laser surgery has the potential to improve visual acuity and enhance overall vision quality as compared with today's conventional LASIK,” said Steven Brint, MD, one of the clinical investigators of the system. “Treating optical aberrations, which impact low-contrast visual acuities such as night driving, will improve the patient's quality of vision.”

Clinical trials are ongoing for the treatment of myopic astigmatism, hyperopia with and without astigmatism and other ocular irregularities, according to Alcon.